Obesity

A state in which body weight is well above the recommended standards, usually because of extra body fat.

Risk factor
In 2 atlases

Overview

Technical summary

MeSH concept M0015159, the preferred concept of descriptor D009765, describes obesity as a state in which body weight is well above recommended standards, usually because of extra body fat, and adds that the standards may vary by age, sex and genetic or cultural background. This identity gives no measurement cut-off and states nothing about risk or treatment.

Definition

Body weight well above the recommended standards, usually because of extra body fat. The standards may vary by age, sex and genetic or cultural background.

Type: Trait

Contexts

None stated in this record.

Claims and evidence

No claims are published for this risk factor yet.

Clinical links

Each link reports what one cited claim says about one population. "Evaluated for" means studied, not shown to work. These links do not show that anything is effective or right for you.

Claim, not a settled fact Evaluated for this: Semaglutide (Evaluated for, seen from the other side)
Applies to Adult
- Adults aged 45 years or older with preexisting cardiovascular disease and a body-mass index of 27 or greater, with no history of diabetes.
- Multicenter trial. The abstract and the registry fields read do not describe the care setting further.
- Multinational. The registry lists the sites by country on the study page.
- Adults aged 45 years or older (registry minimum age 45 years)
Follow-up Mean follow-up 39.8 months. Mean duration of exposure to semaglutide or placebo 34.2 months.
In SELECT, adults aged 45 and over with existing cardiovascular disease, a body-mass index of 27 or more and no history of diabetes took semaglutide 2.4 mg once a week or placebo. Over a mean follow-up of 39.8 months, a first major cardiovascular event (death from cardiovascular causes, nonfatal heart attack or nonfatal stroke) occurred in 569 of 8803 people (6.5%) on semaglutide and 701 of 8801 (8.0%) on placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90). More people on semaglutide stopped the medicine permanently because of an adverse event: 1461 (16.6%) against 718 (8.2%) on placebo.
Limitations. One double-blind trial, funded by Novo Nordisk (named in the abstract). It enrolled people with existing cardiovascular disease and overweight or obesity who did not have diabetes, so it says nothing about people with diabetes, people without existing cardiovascular disease, or adults under 45. Only the PubMed abstract was read, not the full paper. The abstract reports no certainty grade.

Record details

Record id: core:obesity
Content hash: 3b22732b963921b3b3100612ae5a03d7435e89c05b461ba03265b09515d3887d